IXICO plc Presentation of Assessa® PML at ECTRIMS (6232J)
September 13 2016 - 1:00AM
UK Regulatory
TIDMIXI
RNS Number : 6232J
IXICO plc
13 September 2016
IXICO presents Assessa(R) PML digital healthcare platform
supported by Biogen
at International Multiple Sclerosis Congress
13 September 2016, IXICO plc (AIM: IXI) ('IXICO' or the
'Company'), the brain health company, is presenting its Assessa(R)
PML digital healthcare platform at the European Committee for
Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress on
16 September 2016. Assessa(R) PML is based on IXICO's existing
Assessa(R) technology, and has been designed as part of a
collaboration including IXICO, clinical experts in specialist
centres in The Netherlands, Germany, Switzerland, France, Italy,
Spain and UK, with financial support from Biogen Inc., (NASDAQ:
BIIB) through a collaboration agreement announced in October
2015.
Progressive Multifocal Leukoencephalopathy (PML) is a
potentially fatal side effect of certain drug treatments for
Multiple Sclerosis (MS). Assessa(R) PML is designed to be used
alongside such drugs to support the early detection of PML. It
could therefore improve uptake of effective treatments by providing
improved management of PML risks.
The authors of the ECTRIMS presentation describe a consensus
position on the use of the Assessa(R) PML digital platform in a
clinical setting following a confidential structured workshop in
May 2016.
Assessa(R) PML, currently in beta testing with referring
clinicians and expert neuroradiologists in European Centres,
supports clinical decision making by providing access to second
opinion reading expertise of MRI scans from MS patients with PML
suspicion. It facilitates the secure transfer and storage of
patient data and second opinion reports between treating physicians
and expert neuroradiologists. Feedback will be used to enhance the
usability and functionality of Assessa(R) PML prior to production
roll-out.
Derek Hill, CEO of IXICO, said:
"We are delighted to be leading this initiative with our
pharmaceutical and clinical collaborators. The development of
Assessa(R) PML represents clear progress in expanding our digital
technologies across a broad range of brain diseases. This
demonstrates the value of using our Assessa(R) platform in a
clinical setting, enabling physicians to assess and implement the
best therapeutic treatments for patients with Multiple
Sclerosis."
IXICO Exhibition
stand:
Stand Number: E22
Dates: 14-17 September 2016
Poster Presentation:
Title: Creating a consensus evaluation
and expert opinion reporting
platform for brain MRI in Multiple
Sclerosis with higher increased
risk of Progressive Multifocal
Leukoencephalopathy
Authorship: F. Barkhof, S. Llufriu, À.
Rovira, A. Gass, C. Gasperini,
H. Kitzler, J. Hodel, J. Chataway,
T. Ziemssen, M. Wattjes, J. Killestein,
P. Vermersch, J. Hall, S. Grootoonk,
N. Royle, D. Hill, T. Yousry
Session Title: Poster Session 2
Session Date: Friday, 16 September 2016
Session Time: 15:30-17:00
Enquiries:
IXICO plc +44 20 3763 7499
Derek Hill, CEO
Susan Lowther, CFO
Peel Hunt LLP (Nominated
Adviser) +44 20 7418 8900
James Steel / Oliver Jackson
FTI Consulting Limited
(Investor Relations) +44 20 3727 1000
Simon Conway / Mo Noonan
/ Matthew Moss
Notes to Editors
About IXICO
IXICO's innovative and proprietary digital healthcare
technologies help those involved in researching and treating
serious diseases to capture and analyse clinical data to make
rapid, informed decisions. In clinical research this includes the
phenotyping of patients, quantification of disease pathology and
measurement of patient outcomes. In clinical practice the mobile
health and digital decision support technologies aid diagnosis,
patient engagement and monitoring. IXICO is also collaborating with
partners to develop companion digital health products targeted at
improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease,
Huntington's disease, Multiple Sclerosis, behavioural health, child
and adolescent mental health.
More information is available on www.ixico.com
About Progressive Multifocal Leukoencephalopathy (PML)
Progressive Multifocal Leukoencephalopathy (PML) is a severe
side effect of several MS immunotherapeutics and a challenge for
modern treatment strategies. MRI is very sensitive to PML and can
detect asymptomatic PML. However lesion differentiation is
challenging and requires dedicated neuroradiology expertise, which
is scarce outside specialised centres.
About Biogen
Through cutting-edge science and medicine, Biogen discovers,
develops and delivers worldwide innovative therapies for people
living with serious neurological, autoimmune and rare diseases.
Founded in 1978, Biogen is one of the world's oldest independent
biotechnology companies and patients worldwide benefit from its
leading multiple sclerosis and innovative hemophilia therapies.
More information is available on www.biogen.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGGUAUBUPQGBP
(END) Dow Jones Newswires
September 13, 2016 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024